Filing identity and reporting period
The supplied filing is Jupiter Wellness, Inc.’s Form 10-K for the fiscal year ended December 31, 2022, filed April 3, 2023. This does not match the request metadata identifying BONK, Inc. and “2022 Q4”; the filing itself identifies the registrant as Jupiter Wellness, Inc. and reports full-year results.
Business context
Jupiter Wellness develops and sells consumer wellness products and pursues therapeutic-product development and licensing. Its products include skin and sun-care items, vitiligo and psoriasis treatment Photocil, and hair-loss product candidate JW-700. Its wholly owned SRM Entertainment subsidiary sells merchandise to theme parks. The company reported two segments: CBD-based skin and wellness products, and theme-park merchandise. In 2022, SRM generated most reported revenue.
Financial results and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | $6.20 million | $2.88 million |
| Cost of sales | $5.17 million | $2.34 million |
| Gross profit | $1.03 million | $0.54 million |
| Gross margin | 16.6% | 18.6% |
| Operating expenses | $14.97 million | $27.61 million |
| Net loss | $15.22 million | $28.10 million |
| Loss per share, basic and diluted | $0.69 | $1.69 |
| Cash used in operating activities | $6.40 million | $7.57 million |
Revenue increased about 115% year over year, which management attributed to more normalized operations as theme parks reopened after COVID-related disruption. SRM contributed $6.08 million of 2022 revenue, while Jupiter Wellness’s own segment reported $121,000. Consolidated gross margin declined from approximately 18.6% to 16.6%.
Cash fell to $1.93 million at year-end from $11.75 million. Current assets were $6.75 million and current liabilities $4.51 million, for reported working capital of approximately $2.25 million. Total liabilities were $5.03 million. The balance sheet included $2.00 million of convertible notes, a $47,533 SBA loan, and lease liabilities totaling about $684,000. The company reported a $50.60 million accumulated deficit.
Investing cash outflow was $2.47 million and financing cash outflow was $0.96 million in 2022. The filing reports $2.88 million spent repurchasing shares, which were subsequently cancelled. It also reports $1.50 million paid under a clinical research agreement.
Material changes and unusual items
- Net loss narrowed by $12.88 million, mainly alongside a $9.00 million reduction in impairment of the Next Frontier Pharmaceuticals notes and lower stock-based compensation and general and administrative expenses.
- The company recorded a $1.00 million impairment on the Next Frontier notes in 2022, following a $10.00 million impairment in 2021. The proposed acquisition was terminated in February 2022, and the company had issued a notice of default.
- 2022 included $1.45 million of intangible-asset impairment, including a $375,000 write-off of a remaining licensing agreement and a $1.075 million impairment associated with the clinical research agreement. The company also wrote off $152,432 of slow-moving, expired, or discontinued inventory.
- R&D expense was $1.64 million in the financial-statement notes, compared with $1.08 million in 2021. The filing’s MD&A contains an inconsistent R&D figure and other expense-description errors; see investor verification items below.
- In January 2023, the company issued 4.32 million shares at $0.70 per share and arranged warrants to purchase up to 8.63 million shares at $1.00 per share. The combined offerings generated approximately $4.1 million gross and $3.5 million net proceeds.
Outlook, risks, and contingencies
The filing provides no quantified revenue, earnings, or cash-flow guidance. Management described plans to develop products, expand distribution and licensing, and pursue international markets. Taisho planned a commercial JW-700 launch in Japan in 2024; the filing also describes Indian licensing arrangements for JW-700 and Photocil. Photocil launched in India in the third quarter of 2022. These plans depend on partner execution, customer acceptance, and, where applicable, regulatory progress.
The auditor’s report raises substantial doubt about the company’s ability to continue as a going concern, citing recurring losses and working-capital deficiencies. Management described cost controls, limited cash commitments, noncash consideration, and equity financing as possible measures; it also said research and clinical activities could be deferred. The company’s ability to fund operations remains a significant risk.
Other key risks include evolving CBD and FDA regulation, clinical and product-development uncertainty, dependence on third-party manufacturers and licensees, competition, product liability and insurance availability, and dilution from future financing. The company reported no litigation management believed would materially affect its financial position, results, or liquidity. A previously disclosed lawsuit was settled and dismissed with prejudice in February 2023 without a settlement payment by Jupiter.
Management concluded disclosure controls were ineffective and identified a material weakness in internal control over financial reporting related to impairment-testing inputs and resulting audit adjustments. The auditor did not attest to internal-control effectiveness.
Most important facts to verify
- Confirm the issuer and period: this is Jupiter Wellness’s 2022 annual report, not a BONK, Inc. filing or a standalone quarterly report.
- Reconcile inconsistent figures in the filing, including R&D expense (the notes report $1.64 million, while the MD&A contains conflicting text), the operating-expense discussion, and the year-end share count (different sections report 22,388,888 and 22,338,888 shares).
- Review the going-concern disclosure, cash runway, convertible-note maturity and extension terms, and the extent to which the January 2023 financing proceeds address near-term funding needs.
- Assess the recoverability and valuation assumptions for the Next Frontier notes, intangible assets, and clinical research agreement, in light of the impairments and the disclosed material weakness.
- Track post-year-end dilution from the January 2023 share and warrant offerings, and confirm the status of JW-700 licensing and planned launch timelines.